Merck (MRK) stock price jumps after Keytruda survival data; Gardasil layoffs in focus next week
Merck shares closed up 3.8% Friday after reporting Keytruda cut the risk of death by 18% in a late-stage ovarian cancer trial. The company will lay off about 150 workers at a North Carolina Gardasil plant amid weak vaccine demand in China. Investors await management remarks at a March 3 health-care conference. Keytruda accounts for nearly half of Merck’s revenue, with major patents expiring from 2028.